arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Alumis Inc.

ALMS Health Care Biotechnology: Pharmaceutical Preparations
$6.78
▼ -0.4% Today
as of Oct 23, 16:45 ET
Last 30 days -26.46% Sep 14 → Oct 23
$5.81 $6.72 $7.64 $8.56 $9.47 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$6.68
High
$6.82
Low
$6.48
Volume
$1M
Avg Vol
$2M
Mkt Cap
$933M
P/E (TTM)
—
Beta
—
52w High
$31.35
52w Low
$4.38
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 21 items

Oct 9 · 17:11 Clinical Trials Arena
Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
Oct 9 · 08:00 PR GlobeNewswire
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
Sep 10 · 08:02 MT Newswires
Alumis Insider Bought Shares Worth $10,726,255, According to a Recent SEC Filing
▸ Show all 21 press releases & news Free account →

ALMS earnings at a glance

The options market is pricing a move of about ±10.6% after the report, a range of roughly $6.06 to $7.50 from today's $6.78. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±1.0% on average; after the most recent report on May 14, 2026 it moved -0.9%. That means options currently expect more movement than ALMS has typically delivered. ALMS beat the consensus EPS estimate in 1 of its last 4 reported quarters. Implied volatility is currently 89%. The share price of $6.78 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$4.38
$31
9% of range
Avg surprise (last 4)
-9.5%
Avg reaction (last 2)
+0.1%
50% positive
Latest IV / EM
89%
EM ±10.6% · $7 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-23.10$-17.51$-11.92$-6.33$-0.74 Actual $-17.13Actual $-19.76Actual $-21.03Actual $-23.10Actual $-1.73Actual $-1.82Est $-1.47Actual $-1.17Est $-1.11Actual $-1.06Est $-0.92Actual $-0.74Est $-0.79Actual $-1.11 JunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-142M$-91M$-40M$11M$62M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-1.11 — — — — financials
Thu May 14, 2026Mar/2026 $-0.74 $-0.79 +6.3% +59.3% -0.9% earnings
Thu Nov 13, 2025Sep/2025 $-1.06 $-0.92 -15.2% — — earnings
Wed Aug 13, 2025Jun/2025 $-1.17 $-1.11 -5.4% — — earnings
Wed May 14, 2025Mar/2025 $-1.82 $-1.47 -23.8% — +1.1% earnings
Mon Sep 30, 2024Sep 2024 $-1.73 — — — — financials
Sun Jun 30, 2024Jun 2024 $-23.10 — — — — financials
Sun Mar 31, 2024Mar 2024 $-21.03 — — — — financials
Sat Sep 30, 2023Sep 2023 $-19.76 — — — — financials
Fri Jun 30, 2023Jun 2023 $-17.13 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$2M$2M—$2M$3M$17M——
Cost of revenue————————
Gross profit————————
Operating income$-149M$-98M—$-115M$-141M$-102M—$-98M
Net income$-142M$-93M—$-111M$59M$-99M—$-93M
EPS (diluted)$-1.11$-0.74—$-1.06$0.77$-1.82—$-1.73

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$64M$64M$90M$65M$152M$129M$170M$213M
Inventory————————
Total current assets$514M$532M$318M$393M$518M$226M$306M$377M
Total assets$561M$672M$412M$488M$611M$261M$341M$413M
Long-term debt————————
Total liabilities$108M$105M$111M$103M$126M$93M$81M$64M
Total equity$452M$567M$301M$385M$485M$168M$260M$348M

Implied volatility — last 90 days

62%125%189%253%316% Jun 10 — IV 130% · EM ±15.3%Jun 11 — IV 117% · EM ±12.9%Jun 12 — IV 186% · EM ±19.0%Jun 16 — IV 174% · EM ±10.3%Jun 19 — IV 101% · EM ±22.4%Jun 22 — IV 78% · EM ±16.3%Jun 23 — IV 89% · EM ±18.2%Jun 24 — IV 83% · EM ±16.7%Jun 25 — IV 102% · EM ±20.0%Jun 26 — IV 110% · EM ±21.1%Jun 29 — IV 114% · EM ±20.3%Jun 30 — IV 87% · EM ±15.0%Jul 01 — IV 94% · EM ±15.8%Jul 02 — IV 101% · EM ±16.4%Jul 03 — IV 105% · EM ±16.4%Jul 06 — IV 62% · EM ±8.6%Jul 07 — IV 69% · EM ±9.1%Jul 08 — IV 70% · EM ±8.7%Jul 09 — IV 79% · EM ±9.3%Jul 10 — IV 150% · EM ±16.6%Jul 13 — IV 151% · EM ±12.6%Jul 14 — IV 253% · EM ±18.3%Jul 15 — IV 317% · EM ±18.7%Jul 16 — IV 167% · EM ±7.0%Jul 20 — IV 160% · EM ±37.9%Jul 21 — IV 165% · EM ±38.4%Jul 22 — IV 168% · EM ±38.4%Jul 23 — IV 168% · EM ±37.8%Jul 24 — IV 174% · EM ±38.4%Jul 27 — IV 190% · EM ±39.7%Jul 28 — IV 184% · EM ±37.7%Jul 29 — IV 161% · EM ±32.3%Jul 30 — IV 156% · EM ±30.6%Jul 31 — IV 153% · EM ±29.2%Aug 03 — IV 167% · EM ±29.7%Aug 04 — IV 180% · EM ±31.0%Aug 05 — IV 177% · EM ±29.5%Aug 06 — IV 180% · EM ±29.1%Aug 07 — IV 192% · EM ±30.0%Aug 10 — IV 201% · EM ±27.8%Aug 11 — IV 230% · EM ±30.4%Aug 12 — IV 222% · EM ±27.8%Aug 13 — IV 251% · EM ±29.6%Aug 14 — IV 153% · EM ±16.9%Aug 17 — IV 218% · EM ±18.2%Aug 18 — IV 226% · EM ±16.4%Aug 19 — IV 288% · EM ±17.0%Aug 20 — IV 223% · EM ±9.3%Aug 24 — IV 215% · EM ±44.9%Aug 25 — IV 237% · EM ±48.4%Aug 26 — IV 226% · EM ±45.3%Aug 27 — IV 221% · EM ±43.3%Aug 28 — IV 202% · EM ±38.7%Aug 31 — IV 247% · EM ±43.8%Sep 01 — IV 132% · EM ±22.7%Sep 02 — IV 100% · EM ±16.7%Sep 03 — IV 88% · EM ±14.3%Sep 04 — IV 84% · EM ±13.1%Sep 07 — IV 94% · EM ±13.1%Sep 08 — IV 93% · EM ±12.3%Sep 09 — IV 79% · EM ±9.9%Sep 10 — IV 71% · EM ±8.3%Sep 11 — IV 79% · EM ±8.7%Sep 14 — IV 104% · EM ±8.7%Sep 15 — IV 181% · EM ±13.1%Sep 16 — IV 128% · EM ±7.6%Sep 17 — IV 184% · EM ±7.7%Sep 21 — IV 89% · EM ±18.7%Sep 22 — IV 68% · EM ±13.9%Sep 23 — IV 76% · EM ±15.1%Sep 24 — IV 67% · EM ±13.0%Sep 25 — IV 74% · EM ±14.1%Sep 28 — IV 75% · EM ±13.3%Sep 29 — IV 96% · EM ±16.5%Sep 30 — IV 81% · EM ±13.5%Oct 01 — IV 107% · EM ±17.3%Oct 02 — IV 89% · EM ±13.9%Oct 06 — IV 85% · EM ±11.2%Oct 07 — IV 136% · EM ±17.0%Oct 08 — IV 89% · EM ±10.6%

Sector peers

KURA
Kura Oncology, Inc.
$949M $9.61-2.7%
MLTX
MoonLake Immunotherapeutics
$917M $11.85+11.3%
ABUS
Arbutus Biopharma Corporation
$902M $4.20+0.5%
TBPH
Theravance Biopharma, Inc.
$880M $17.030.0%
JBIO
Jade Biosciences, Inc.
$876M $14.59-3.6%
CRVS
Corvus Pharmaceuticals, Inc.
$876M $10.53+4.8%

ALMS earnings FAQ

What is ALMS's expected move for earnings?

Options currently price a move of about ±10.6%, or $0.72 per share either way from $6.78.

How does ALMS stock usually react to earnings?

Across the last 2 reports the average next-day move was ±1.0%, up 1 times and down 1 times.

What is ALMS's implied volatility?

ALMS's at-the-money implied volatility is about 89% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in